Shell Asset Management Co. Grows Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Shell Asset Management Co. boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDPGet Rating) by 35.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,245 shares of the company’s stock after purchasing an additional 586 shares during the period. Shell Asset Management Co.’s holdings in Medpace were worth $336,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of MEDP. Comerica Bank lifted its position in Medpace by 1.4% during the first quarter. Comerica Bank now owns 13,239 shares of the company’s stock valued at $2,119,000 after purchasing an additional 187 shares in the last quarter. Hardy Reed LLC purchased a new position in Medpace during the first quarter valued at $135,000. Park Avenue Securities LLC lifted its position in Medpace by 28.3% during the first quarter. Park Avenue Securities LLC now owns 1,473 shares of the company’s stock valued at $241,000 after purchasing an additional 325 shares in the last quarter. Signaturefd LLC raised its holdings in Medpace by 486.7% during the first quarter. Signaturefd LLC now owns 264 shares of the company’s stock valued at $43,000 after acquiring an additional 219 shares during the period. Finally, Mutual of America Capital Management LLC raised its holdings in Medpace by 8.1% during the first quarter. Mutual of America Capital Management LLC now owns 59,023 shares of the company’s stock valued at $9,656,000 after acquiring an additional 4,443 shares during the period. 83.97% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 6,500 shares of the business’s stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of $220.53, for a total transaction of $1,433,445.00. Following the sale, the general counsel now directly owns 14,854 shares of the company’s stock, valued at $3,275,752.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Medpace news, General Counsel Stephen P. Ewald sold 6,500 shares of the business’s stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of $220.53, for a total transaction of $1,433,445.00. Following the sale, the general counsel now directly owns 14,854 shares of the company’s stock, valued at $3,275,752.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO August J. Troendle bought 62,515 shares of the company’s stock in a transaction on Monday, September 12th. The shares were acquired at an average price of $167.58 per share, with a total value of $10,476,263.70. Following the transaction, the chief executive officer now directly owns 5,893,172 shares of the company’s stock, valued at $987,577,763.76. The disclosure for this purchase can be found here. Insiders have purchased 489,768 shares of company stock valued at $77,322,137 over the last ninety days. 20.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on MEDP. Robert W. Baird raised their price target on Medpace from $145.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, October 25th. StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a report on Friday, October 28th. Finally, UBS Group raised Medpace from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $142.00 to $238.00 in a report on Thursday, October 27th.

Medpace Trading Down 3.4 %

Shares of MEDP stock opened at $217.68 on Friday. Medpace Holdings, Inc. has a 12-month low of $126.94 and a 12-month high of $235.72. The stock’s 50-day moving average price is $178.77 and its 200-day moving average price is $160.82. The stock has a market capitalization of $6.77 billion, a price-to-earnings ratio of 33.39 and a beta of 1.47.

Medpace (NASDAQ:MEDPGet Rating) last issued its quarterly earnings data on Monday, October 24th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.58. Medpace had a return on equity of 41.39% and a net margin of 16.50%. The company had revenue of $383.74 million for the quarter, compared to analysts’ expectations of $357.17 million. During the same period in the previous year, the firm posted $1.29 earnings per share. The firm’s revenue for the quarter was up 29.8% on a year-over-year basis. As a group, research analysts predict that Medpace Holdings, Inc. will post 6.97 EPS for the current fiscal year.

Medpace Profile

(Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Recommended Stories

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPGet Rating).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.